Sonnet BioTherapeutics Holdings, Inc. (SONN)
NASDAQ: SONN · IEX Real-Time Price · USD
0.850
-0.014 (-1.59%)
At close: Jul 19, 2024, 4:00 PM
0.860
+0.010 (1.18%)
Pre-market: Jul 22, 2024, 8:17 AM EDT
SONN Employees
Sonnet BioTherapeutics Holdings had 12 employees as of September 30, 2023. The number of employees did not change compared to the previous year.
Employees
12
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$7,728
Profits / Employee
-$702,214
Market Cap
4.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 12 | 0 | - |
| Sep 30, 2022 | 12 | 3 | 33.33% |
| Sep 30, 2021 | 9 | 0 | - |
| Sep 30, 2020 | 9 | -21 | -70.00% |
| Sep 30, 2019 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genetic Technologies | 60 |
| Predictive Oncology | 35 |
| Trevena | 23 |
| Theriva Biologics | 22 |
| CERo Therapeutics Holdings | 9 |
| Portage Biotech | 7 |
| Allarity Therapeutics | 6 |
| MyMD Pharmaceuticals | 6 |
SONN News
- 7 weeks ago - Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting - GlobeNewsWire
- 2 months ago - Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target - Accesswire
- 2 months ago - Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update - Accesswire
- 2 months ago - Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference - Accesswire
- 4 months ago - Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting - Accesswire
- 4 months ago - Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective - Accesswire
- 5 months ago - Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers - Accesswire
- 5 months ago - Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update - Accesswire